心血管药物治疗的进展. 一,心脏肌抑制剂
Paul S Pagel1, Dustin Hang1, Julie K Freed1
1Department of Anesthesiology, the Medical College of Wisconsin, Milwaukee, WI.
Journal of cardiothoracic and vascular anesthesia
|February 25, 2025
概括
新型心脏肌肉酶抑制剂为高缩小型心肌病 (HCM) 提供了有前途的治疗方法,解决了该疾病的根本原因. 这些药物,如mavacamten和aficamten,代表了超越HCM患者传统症状管理的重大进步.
科学领域:
- 心脏病学 心脏病学
- 分子医学是分子医学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 超性心肌病变 (HCM) 是一种常见的遗传性心脏病.
- HCM涉及左心室重塑,外流阻塞和心律失常,往往导致心脏突然死亡.
- 目前的治疗方法可以控制症状,但不能控制HCM的潜在分子病理.
研究的目的:
- 审查新型心脏肌肉酶抑制剂的分子机制.
- 讨论HCM中mavacamten和aficamten最近的临床试验数据.
- 探索这些药物在其他心力衰竭类型中的潜力及其麻醉影响.
主要方法:
- 对心脏肌肉酶抑制剂的分子机制的审查.
- 对mavacamten和aficamten最近的临床试验数据的分析.
- 讨论未来的研究和潜在的应用在心力衰竭与保存的喷射分数 (HFpEF) 和术后护理.
主要成果:
- 心脏肌肉酶抑制剂向HCM的潜在化学机械循环.
- 马瓦卡门和阿菲卡门在临床试验中显示出改善HCM表型的前景.
- 这些抑制剂可能为HFpEF提供新的治疗途径,并且需要在外科外科设置中考虑.
结论:
- 心脏肌抑制剂代表了HCM的新疗法类别,准其核心分子缺陷.
- 马瓦卡门特和阿菲卡门特正在领导这个类别,正在进行的研究正在探索它们的全部临床实用性.
- 这些药物的应用可能超出HCM范围,它们的外科手术期效应需要注意.
相关概念视频
Heart Failure Drugs: Inotropic Agents
498
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
498
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
370
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
370
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
437
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
437
Heart Failure Drugs: β-Blockers
308
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
308
Antihypertensive Drugs: Vasodilators
456
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
456
Pathophysiology of Cardiac Performance
509
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
509


